Literature DB >> 18577511

Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors.

Ira B Dicker1, Brian Terry, Zeyu Lin, Zhufang Li, Sagarika Bollini, Himadri K Samanta, Volodymyr Gali, Michael A Walker, Mark R Krystal.   

Abstract

In this study, eight different HIV-1 integrase proteins containing mutations observed in strand transfer inhibitor-resistant viruses were expressed, purified, and used for detailed enzymatic analyses. All the variants examined were impaired for strand transfer activity compared with the wild type enzyme, with relative catalytic efficiencies (k(p)/K(m)) ranging from 0.6 to 50% of wild type. The origin of the reduced strand transfer efficiencies of the variant enzymes was predominantly because of poorer catalytic turnover (k(p)) values. However, smaller second-order effects were caused by up to 4-fold increases in K(m) values for target DNA utilization in some of the variants. All the variants were less efficient than the wild type enzyme in assembling on the viral long terminal repeat, as each variant required more protein than wild type to attain maximal activity. In addition, the variant integrases displayed up to 8-fold reductions in their catalytic efficiencies for 3'-processing. The Q148R variant was the most defective enzyme. The molecular basis for resistance of these enzymes was shown to be due to lower affinity binding of the strand transfer inhibitor to the integrase complex, a consequence of faster dissociation rates. In the case of the Q148R variant, the origin of reduced compound affinity lies in alterations to the active site that reduce the binding of a catalytically essential magnesium ion. Finally, except for T66I, variant viruses harboring the resistance-inducing substitutions were defective for viral integration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18577511      PMCID: PMC3259799          DOI: 10.1074/jbc.M804213200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors.

Authors:  Deborah J Lee; W Edward Robinson
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Retroviral DNA integration: reaction pathway and critical intermediates.

Authors:  Min Li; Michiyo Mizuuchi; Terrence R Burke; Robert Craigie
Journal:  EMBO J       Date:  2006-02-16       Impact factor: 11.598

Review 3.  Integrase inhibitors to treat HIV/AIDS.

Authors:  Yves Pommier; Allison A Johnson; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2005-03       Impact factor: 84.694

4.  Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.

Authors:  S Kehlenbeck; U Betz; A Birkmann; B Fast; A H Göller; K Henninger; T Lowinger; D Marrero; A Paessens; D Paulsen; V Pevzner; R Schohe-Loop; H Tsujishita; R Welker; J Kreuter; H Rübsamen-Waigmann; F Dittmer
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

Authors:  D J Hazuda; P Felock; M Witmer; A Wolfe; K Stillmock; J A Grobler; A Espeseth; L Gabryelski; W Schleif; C Blau; M D Miller
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

6.  Oligomeric states of the HIV-1 integrase as measured by time-resolved fluorescence anisotropy.

Authors:  E Deprez; P Tauc; H Leh; J F Mouscadet; C Auclair; J C Brochon
Journal:  Biochemistry       Date:  2000-08-08       Impact factor: 3.162

7.  Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.

Authors:  Ira B Dicker; Himadri K Samanta; Zhufang Li; Yang Hong; Yuan Tian; Jacques Banville; Roger R Remillard; Michael A Walker; David R Langley; Mark Krystal
Journal:  J Biol Chem       Date:  2007-08-21       Impact factor: 5.157

8.  Kinetic study of the HIV-1 DNA 3'-end processing.

Authors:  Maksim Smolov; Marina Gottikh; Vadim Tashlitskii; Sergei Korolev; Ilya Demidyuk; Jean-Claude Brochon; Jean-François Mouscadet; Eric Deprez
Journal:  FEBS J       Date:  2006-03       Impact factor: 5.542

9.  Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).

Authors:  Kazuya Shimura; Eiichi Kodama; Yasuko Sakagami; Yuji Matsuzaki; Wataru Watanabe; Kazunobu Yamataka; Yasuo Watanabe; Yoshitsugu Ohata; Satoki Doi; Motohide Sato; Mitsuki Kano; Satoru Ikeda; Masao Matsuoka
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

10.  HIV-1 integrase crosslinked oligomers are active in vitro.

Authors:  Aurélie Faure; Christina Calmels; Cécile Desjobert; Michel Castroviejo; Anne Caumont-Sarcos; Laura Tarrago-Litvak; Simon Litvak; Vincent Parissi
Journal:  Nucleic Acids Res       Date:  2005-02-17       Impact factor: 16.971

View more
  15 in total

1.  Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.

Authors:  Maame Efua S Sampah; Lin Shen; Benjamin L Jilek; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

2.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

3.  Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.

Authors:  Kendra E Hightower; Ruolan Wang; Felix Deanda; Brian A Johns; Kurt Weaver; Yingnian Shen; Ginger H Tomberlin; H Luke Carter; Timothy Broderick; Scott Sigethy; Takahiro Seki; Masanori Kobayashi; Mark R Underwood
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

4.  Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.

Authors:  Peter K Quashie; Maureen Oliviera; Tamar Veres; Nathan Osman; Ying-Shan Han; Said Hassounah; Yolanda Lie; Wei Huang; Thibault Mesplède; Mark A Wainberg
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

5.  Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.

Authors:  Krishan K Pandey; Sibes Bera; Ajaykumar C Vora; Duane P Grandgenett
Journal:  Biochemistry       Date:  2010-09-28       Impact factor: 3.162

6.  Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.

Authors:  Andrea Low; Nicole Prada; Michael Topper; Florin Vaida; Delivette Castor; Hiroshi Mohri; Daria Hazuda; Mark Muesing; Martin Markowitz
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

7.  Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.

Authors:  Vasu Nair; Maurice Okello; Sanjay Mishra; Jon Mirsalis; Kathleen O'Loughlin; Yu Zhong
Journal:  Antiviral Res       Date:  2014-05-10       Impact factor: 5.970

8.  Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance.

Authors:  Monika Tschochner; Abha Chopra; Tanya M Maiden; Imran F Ahmad; Ian James; Hansjakob Furrer; Huldrych F Günthard; Simon Mallal; Andri Rauch; Mina John
Journal:  Antivir Ther       Date:  2009

9.  Resistance to integrase inhibitors.

Authors:  Mathieu Métifiot; Christophe Marchand; Kasthuraiah Maddali; Yves Pommier
Journal:  Viruses       Date:  2010-06-25       Impact factor: 5.048

Review 10.  Novel therapeutic strategies targeting HIV integrase.

Authors:  Peter K Quashie; Richard D Sloan; Mark A Wainberg
Journal:  BMC Med       Date:  2012-04-12       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.